Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ME-344 plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer
NCT05824559Phase 1Terminated
- Sponsor
- MEI Pharma
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ME-344 in colorectal cancer (CRC), sponsored by MEI Pharma. Primary endpoint: Progression Free Survival Rate at 16 Weeks. Started Aug 2023; status: terminated.
02
Drugs
ME-344
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05824559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824559.